Lyra Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript
All right. Welcome back, everyone, to H.C. Wainwright's 25th Annual Global Investment Conference. My name is Matthew Caufield. I'm a biotechnology equity research analyst here at HCW.
We're very pleased to now have a fireside chat with Lyra Therapeutics, and I'd like to welcome President and CEO Maria Palasis. Thank you very much for being here.
Thank you, Matthew. It's great to be here.
Questions & Answers
Excellent. Well, we're very excited. Obviously, the team recently had their Phase 2 positive top line for the BEACON trial for candidate LYR-220 in post-surgical CRS. So maybe just before we dive into that topic and kind of all the progress you guys have been up to, maybe just, at a high level, you could tell us a little bit about your company's strategic focus, sort of your disease focus, the unmet need.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
